Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint - HER2 Support Group Forums

		HER2 Support Group Forums > General Cancer News
Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

General Cancer News Latest Breast Cancer News from Moreover Technologies

Prev

Previous Post

Next Post

Next

06-03-2012, 10:20 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,959	Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS). More...

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 05:01 AM.

free webpage hit counter